Clinical Research Directory
Browse clinical research sites, groups, and studies.
High-dose Cephalexin for Cellulitis (HI-DOCC)
Sponsor: Ottawa Hospital Research Institute
Summary
Cellulitis is a common condition diagnosed and managed in the ED that carries significant burden on healthcare systems globally. Cellulitis is the 8th most common reason patients present to an ED in Canada. Among middle-aged patients (45-64 years) it is the 5th most common reason to visit an ED. This disease is responsible for significant healthcare system burden due to high hospitalization rates and subsequent costs. The Investigators conducted a health records review at two large urban EDs in Ottawa, and found that 29.6% of patients with cellulitis are admitted to hospital. In a separate study, The investigators found that the mean cost of care to hospitalize cellulitis patients for IV antibiotics was $10,145 CDN.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
446
Start Date
2023-08-30
Completion Date
2026-08-01
Last Updated
2025-10-01
Healthy Volunteers
Yes
Conditions
Interventions
Cephalexin
1000 mg PO QID for 7 days
Cephalexin
500 mg PO QID plus oral placebo for 7 days
Locations (10)
South Health Campus
Calgary, Alberta, Canada
Queen Elisabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Health Sciences North
Greater Sudbury, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Thunder Bay Health Sciences Centre
Thunder Bay, Ontario, Canada
Sinai Health System
Toronto, Ontario, Canada
Hôpital du Sacré-Cœur de Montréal
Montreal, Quebec, Canada
Enfant-Jésus Hospital
Québec, Quebec, Canada